Antiplatelet Therapy in Acute Mild-Moderate Ischemic Stroke
Status:
Recruiting
Trial end date:
2022-04-30
Target enrollment:
Participant gender:
Summary
The risk of early recurrence or progression of acute ischemic stroke is very high, even in
patients treated with aspirin. The Chance study show that clopidogrel plus aspirin treatment
reduced the risk of recurrent stroke in patients with transient ischemic attack (TIA) or
minor ischemic stroke (NIHSS ≤ 3) within 24 hour onset and was not associated with increased
hemorrhage events, compared with aspirin monotherapy. However, it is not known whether the
dual antiplatelet treatment could reduce the risk of early recurrence or progression in
patients with acute mild to moderate ischemic stroke (4 ≤ NIHSS ≤ 10). The investigators
hypothesise that clopidogrel-aspirin treatment will be superior to aspirin monotherapy in
this group of patients.